Back to Search
Start Over
Plaminogen activator inhibitor-type 1: Its plasma determinants and relation with cardiovascular risk
- Source :
- Scopus-Elsevier
-
Abstract
- SummaryThe habitual level of PAI-1 is influenced by many factors, of which obesity and insulin resistance are the most important. It is possible to reduce plasma PAI-1 by changes in life style, e.g. weight reduction and physical activity. Data on potential interactions between environmental and metabolic variables on one hand, and the 4G/5G-polymorphism on the other hand, are still scarce. It becomes more and more clear that PAI-1 may possibly not be a major (causal) factor in cardiovascular disease, but its role in inflammation deserves further attention. In the presence of the 4G-allele not only the PAI-1 response was more pronounced, but also the response of other acute-phase reactants, which implies that the increases of these reactants are secondary to the increase in PAI-1. A myocardial infarction also provokes an acute phase response. It can thus be hypothesized that the 4G-allele might exacerbate tissue injury during the acute phase after a myocardial infarction, and thereby negatively affect the prognosis.
- Subjects :
- medicine.medical_specialty
Polymorphism, Genetic
business.industry
Acute-phase protein
Inflammation
Hematology
Disease
medicine.disease
Coronary artery disease
chemistry.chemical_compound
Endocrinology
Insulin resistance
chemistry
Cardiovascular Diseases
Risk Factors
Weight loss
Plasminogen activator inhibitor-1
Internal medicine
Plasminogen Activator Inhibitor 1
Immunology
Humans
Medicine
Myocardial infarction
medicine.symptom
business
Subjects
Details
- Database :
- OpenAIRE
- Journal :
- Scopus-Elsevier
- Accession number :
- edsair.doi.dedup.....7b9d9ba775935cef711f18e13aafc6a4